Acute dialytic support for the critically ill: Continuous venovenous haemodialysis versus continuous venovenous haemofiltration

International Medical Journal

Volumn 13, Issue 1, 2006, Pages 37-42

  Daud, Kamaliah Mohd ^a   Leong, Goh Bak ^b   Visvanathan, Ravindran ^c  

^a SCHOOL OF HEALTH SCIENCES   (Malaysia)

^b Hospital Selayang   (Malaysia)

^c HOSPITAL KUALA LUMPUR   (Malaysia)

Author keywords

Acute renal failure; Cytokines; Haemofiltration; Venovenous haemodialysis

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CHEMICAL ANALYSIS; CLINICAL TRIAL; CONTINUOUS HEMODIALYSIS; CONTINUOUS HEMOFILTRATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; CRITICAL ILLNESS; FEMALE; HUMAN; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL TIME; URINE VOLUME; VITAL SIGN;

EID: 33645832382     PISSN: 13412051     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Nissenson AR. Acute renal failure: definition and pathogenesis. Kidney Int 1998; 53(Suppl 66): S7-10.
2. Cameron JS. Acute renal failure thirty years on. Q J Med 1990; 74: 1-2.
3. Turney JH, Marshall DH, Brownjohn AM, Ellis CM, Parsons FM. The evolution of acute renal failure, 1956-88. Q J Med 1990; 74: 83-104.
4. Chew SL, Lins RL, Daelemens R, De Broe ME. Outcome in acute renal failure. Nephrol Dial Transplant 1993; 8: 101-107.
5. Briglia A, Paganini EP. Acute renal failure in the intensive care unit: therapy overview, patient risk stratification, complications of renal replacement, and special circumstances. Clin Chest Med 1999; 20: 347-66.
6. Schetz MRC. Classical and alternative indications for continuous renal replacement therapy. Kidney Int 1998; 53(Suppl 66): S129-32.
7. Ronco C, Bellomo R, eds. Critical care nephrology. Dordrecht, Netherlands: Kluwer Academic Publishers, 1998.
8. Bellomo R, Mansfield D, Rumble S, Shapiro J, Parkin G, Boyce N. A comparison of conventional dialytic therapy and acute continuous haemodiafiltration in the management of acute renal failure in the critically ill. Ren Fail 1993; 15: 595-602.
9. Jones CH, Richardson D, Goutcher E, et al. Continuous venovenous high flux dialysis in multiorgan failure: a 5 year single center experience. Am J Kidney Dis 1998; 31: 227-33.
10. Forni LG, Hilton PJ. Continuous haemofiltration in the treatment of acute renal failure. N Engl J Med 1997; 18: 1303-9.
11. Kierdorf H, Sieberth HG. Continuous treatment modalities in acute renal failure. Nephrol Dial Transplant 1995; 10: 2001-8.
12. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomized trial. Lancet 2000; 355: 26-30.
13. Brunet S, Leblanc M, Geadah D, et al. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999; 34: 486-92.
14. Bellomo R. Choosing a therapeutic modality: Hemofiltration vs hemodialysis vs hemodiafiltration. Seminars in Dialysis 1996; 9: 88-92.
15. Kellum JA, Johnson JP, Kramer D, et al. Diffusive vs convective therapy: Effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome. Crit Care Med 1998; 26: 1995-2000.
16. Schaefer JH, Jochimsen F, Keller F, Wegscheider K, Distler A. Outcome prediction of acute renal failure in medical intensive care. Intensive Care Med 1991; 17: 19-24.
17. Heering P, Ivens K, Thumer O, et al. The use of dialysate buffers during continuous hemofiltration in critically ill patients with acute renal failure. Intensive Care Med 1999; 25: 1244-1251.
18. Heering P, Morgera S, Schmitz FJ, et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 1997; 23: 288-296.
19. Sasse KC, Nauenberg E, Long A, Anton B, Tucker HJ, Hu TW. Long-term survival after intensive care unit admission with sepsis. Crit Care Med 1995; 23: 1040-1047.
20. Palevsky PM. Continuous venovenous haemodialysis: Technical Consideration Uptodate Aug 2004; version 12.3: page 1.
21. Waage A, Brandtzaeg P, Halstensen A, Kierluf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989; 169: 333-338.
22. Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1988; 1: 355-357.
23. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumour necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17: 975-978.
24. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Eng J Med 1988; 318: 1481-1486.
25. Hoffman JN, Hartl WH, Deppisch R, et al. Haemofiltration in human sepsis: Evidence for elimination of immunomodulatory substances. Kidney Int 1995; 48: 1563.
26. Barzilay E, Kessler D, Berlot G, et al. Use of extracorporeal supportive techniques as additional treatment for septic-induced multiple organ failure patients. Crit Care Med 1989; 17: 634.
27. De Vriese AS, Vanholder RC, De Suffer JH, et al. Continuous renal replacement therapies in sepsis: Where are the data? (editorial). Nephrol Dial Transplant 1998; 13: 1362.